<DOC>
	<DOCNO>NCT02588677</DOCNO>
	<brief_summary>The objective compare efficacy safety masitinib combination riluzole treatment patient suffer Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>The Objective Compare Efficacy Safety Masitinib Combination With Riluzole Treatment Patients Suffering From Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Masitinib novel tyrosine kinase inhibitor target microglia mast cell inhibit limited number kinase . Masitinib block microglia proliferation activation , mast cell-mediated degranulation , release cytotoxic substance might damage motor nerve .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Main inclusion criterion : 1 . Familial sporadic ALS 2 . Patient diagnose laboratory support , clinically probable definite ALS 3 . Patient treat stable dose riluzole ( 100 mg/day ) least 30 day prior screen 1 . Patient underwent tracheostomy and/or gastrostomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis ( ALS ) - masitinib</keyword>
</DOC>